Clinical Trials Browser

Completed × devimistat × Plasma cell × Clear all

NCT01034475 2018-07-02

Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies

Phase 1 Completed

LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma